Four out of nine national US healthcare payers and five of at least one regional payers said they were very concerned about the financial risk associated with gene therapies, according to a survey by the National Pharmaceutical Council and Analysis Group . It also found all national and 50% of regional plans would consider at least one alternative payment method for gene therapy treatments in the next three years . Taken individually, these financial challenges are not new, as other therapies have faced them in the past to some degree. Almost all said payment would be dependent on performance-based requirements, while 50% said non-response to a treatment would be a 'deal breaker'.
Four out of nine national US healthcare payers and five of at least one regional payers said they were very concerned about the financial risk associated with gene therapies, according to a survey by the National Pharmaceutical Council and Analysis Group . It also found all national and 50% of regional plans would consider at least one alternative payment method for gene therapy treatments in the next three years . Almost all said payment would be dependent on performance-based requirements, while 50% said non-response to a treatment would be a 'deal breaker'.